Siolta Therapeutics, a clinical-stage biotech company and MBC BioLabs San Carlos resident company, has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H.
Amgen and MBC BioLabs announced that BigHat Biosciences and Trilo Therapeutics have each been awarded an Amgen Golden Ticket to MBC BioLabs.
Symbiome is slated to launch Oct. 7 with seven products that aim to shift the skin’s microbiome back to its “ancestral” state, according to Larry Weiss, founder and chief scientific officer.
Andres Grechi, Principal and Design Director at MBH Architects, talks about his insights on how his team helped complete a facility that may prove to be a game-changer in the ﬁght against the COVID-19
The SPARK program at Stanford is a partnership between Stanford researchers and volunteer experts from the biotechnology ecosystem that provides education and mentorship.
Online Lab Manager introduces 930 Brittan Ave in San Carlos
XPose Therapeutics embarks on the discovery and development of novel oncology medicines targeting DNA Damage Response with non-dilutive funding from NCI
XPose Therapeutics is leveraging 3D structures of molecular fragments bound to drug targets to develop specific therapeutics.
2020 Servier Golden Ticket will be awarded in early September!